Next Day Disclosure Return
Filed with HKEX · · 6 pages · English
Earlier from PegBio
Later from PegBio
- Voluntary announcement core product Visepegenatide injection passed the preliminary review in accordance with the 2026 national reimbursement drug list adjustment
- Proposed change of auditor
- Change in use of proceeds from the global offering
- 2026 Interim Report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow PegBio into a list and get an email when it puts out news.
Follow PegBio